Dr Gluz talks to ecancertv at SABCS 2015 about biomarker driven clinical trials and the WSG-ADAPT TN randomised phase II trial.
WSG-ADAPT TN is an adjuvant dynamic marker-adjusted personalised therapy trial, optimising risk assessment and therapy response prediction in early breast cancer.